Retinal Vein Occlusion Market Research, Future Developments, Industry Revenue and Competitive Landscape Analysis
Retinal
Vein Occlusion Market – Overview
Retinal vein
occlusion is a commonly occurring vascular disorder of the retina; the increasing frequency has contributed
positively to the development of the market. Focused market reports related to the healthcare industry
among others lately have been made available by Market Research
Future which issues reports on this industry. The Retinal
Vein Occlusion market Research is
anticipated to expand with a CAGR of 15.56% to reach USD 14.350 in the duration
of the forecast period.
The market’s growth is inspired by the rising number of cases
related to lymphoma and multiple myeloma. Growing prevalence of eye diseases
and prolonged diseases such as diabetes are the main
risk factors for eye diseases. An increasing
level of spending has also enhanced the market because of the research and development by market players. The rise
in the level of anti VEGF drugs has increased the development of the
market to a great extent and is projected to
continue to do so in the forecast period.
Industry
Segments
The retinal vein
occlusion market is segmented on the basis of condition, type, treatment,
diagnosis, and end user.
On
the basis of the condition, the market is segmented into ischemic and non-ischemic.
The type based
segmentation of the market comprises of central retinal vein occlusion and
branch retinal artery occlusion.
The basis of
segmentation on treatment comprises of corticosteroid drugs, antivascular
endothelial growth factor, laser retinal photocoagulation, and others.
Based on the
diagnosis, it is segmented into optical
coherence tomography (OCT), fundoscopic examination, fluorescein angiography, and others.
The
market is segmented on the basis of end users into
research & academics centers, hospitals and clinics, and others.
Detailed
Regional Analysis
The regional
analysis of the Retinal Occlusion Market
observes that the Americas region controls the retinal vein occlusion market
due to the growing prevalence of patients, the incidence of key market
companies and development of surgical results. Factors such as the incidence of
a strong economic condition and emphasis of research institutions on updating
technology for new and advanced treatment methods for retinal vein occlusion
are further boosting the market in the region. The
European region controls the second place in the market due to growing backing
from the government, the existence of huge geriatric population, and escalated
healthcare spending. The Asia Pacific region is the most rapidly mounting
market due to an increasing number of emerging nations present in this region,
such as nations like China and India. These nations are inspiring the
development of the retinal vein occlusion market. Meanwhile, the Middle
East & African region is anticipated to control the biggest market share
owing to limited accessibility to medical facilities, and slower development of
the healthcare domain. Though, nations such as Kuwait and Qatar are
concentrating more on the healthcare sector and
emerging medical facilities, which will increase the market of this region.
Global Competitive Analysis
The
forecast for development and improvement has developed at a rapid pace changing
the market. The vital trends and players have established an optimistic tone
for development. The greatest chances are being
involved and converted to altering the development pace of the market
considerably. By safeguarding the supply and
demand, the competitors can capture novel opportunities for progress.
The stimulus for the market’s growth has
developed the competitive backdrop of the market. The competitors in the market
have been enthused to ideate strategic
road-maps that utilize the constructive market cues.
Allergan
PLC, Bayer, Bristol-Myers Squibb, Ellex Medical Lasers Ltd, GlaxoSmithKline
PLC, IRIDEX Corporation, Lumenis, Novartis AG, NIDEK CO., LTD, Regeneron
Pharmaceuticals, Hoffmann-La Roche AG, Quantel Medical Inc., Topcon Medical
Systems, Inc., ZEISS
Industry Updates:
Mar 2018 A
biopharmaceutical company Clearside Biomedical, Inc, is creating first-in-class
drug therapies to treat back-of-the-eye diseases, recently announced the
registration of their first patient in Phase
3 clinical trial named TOPAZ of suprachoroidal CLS-TA used with an
intravitreally administered anti-VEGF agent for the treatment of macular edema
associated with Retinal Vein Occlusion. Clearside’s exclusive suspension of the
corticosteroid triamcinolone acetonide, Suprachoroidal CLS-TA, is created for
the administration to the back of the eye
through the suprachoroidal space, or SCS, which is the space situated in the middle of the choroid and the outer protective
layer of the eye recognized as the sclera.
About Market Research
Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact
Market Research Future (part of Wantstats Research
and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment